Skip to main content

The below clickable headlines link directly to outside media outlets, which featured UNC School of Medicine faculty starting Friday, May 8, 2025.


UNC Researchers Uncover Molecular Mechanism Behind Hydralazine-Induced ANCA Vasculitis – Dr. Meghan Free (Newswise)

Patient Selection Is Crucial for Later-Line Treatment Decisions in Metastatic Melanoma – Dr. Stergios Moschos (OncLive)

NC hospitals in state of standby, preparing as measles threat grows – Dr. David Wohl (WRAL-TV)

6 fruits with more vitamin C than an orange – Shelly Wegman (NBC)

Eupraxia Pharmaceuticals Announces Sustained Positive Treatment Outcomes in Patients with Eosinophilic Esophagitis (EoE) After Nine Months of Receiving EP-104GI – Dr. Evan S. Dellon (Small Business Online Network)

Even simple exercises like stretching could slash Alzheimer’s risk and boost brain health, studies show – Dr. Patrick J. Smith (Natural News)

“Health policy expert highlights the importance of state-level urology advocacy.” – Dr. Hans Arora (Urology Times)

Advancing Diagnostic Excellence in Prostate Cancer: Insights From the Quality Summit on Prostate MRI.”  Dr. Zachary Feuer, Dr. Hung-Jui (Ray) Tan, Dr. Mathew Nielsen (AUA News)

Bevacizumab Addition May Be Beneficial for Melanoma Brain Metastases, Study Suggests – Dr. Stergios Moschos (oncologynewscentral.com)

Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease – Dr. Evan S. Dellon (USA Life Sciences Database)

Hepatitis A Outbreak in Los Angeles: Everything We Know – Dr. Stanley Lemon (Newsweek)

Your baby’s PURPLE crying is difficult but normal – Dr. Adam Zolotor (WRAL-TV)

Understanding treatment options for rosacea – Dr. Margaret Coates (WRAL-TV)

Early Studies Suggest GLP-1s May Improve COPD Symptoms – Dr. M. Bradley Drummond (MSN.com)

Early Studies Suggest GLP-1s May Improve COPD Symptoms – Dr. M. Bradley Drummond (Verywell Health)

Eupraxia Pharmaceuticals to Host Virtual KOL Event to Discuss the Phase 1b/2a RESOLVE Study of EP-104GI for the Treatment of Eosinophilic Esophagitis (EoE) on May 9, 2025 – Dr. Evan Dellon (GlobeNewswire)

Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update – Dr. James (Chip) F. Howard (Scitech News Network)